Keytruda (pembrolizumab)

Phase II study of 1L pembrolizumab in pts ≥ age 70 with PDL1+ NSCLC by @NadalErnest and @gecp_org now @LungCaJournal. 1Y OS rate 62% with mOS 19.2m. Confirms expectations, helpful to have prospective data. Age should not deter proper therapy. https://t.co/SqLywYzNK1 (@StephenVLiu)

Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)

WATCH: @shilpaonc, of @ClevelandClinic, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in metastatic urothelial carcinoma & highlights next steps for frontline enfortumab vedotin & pembrolizumab in the phase 3 EV-302 trial. #oncology https://t.co/oZoRVYR0cX (@OncLive)

Here, @jasonlukemd shares insight into the final distant metastasis-free survival analysis of #KEYNOTE716 as presented at the @ASCO annual meeting. Learn more here: https://t.co/Nf8A1JbYCH #onctwitter #medtwitter #ASCO2023 #melanoma #pembrolizumab (@OncLearnNetwork)

According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)

11/16 #TumorBoardTuesday #RCC Back to our case 🔎 👨🏼‍🦳 Patient starts cabozantinib at 60mg qd 📆 3 mos ✋🏽🦶🏽G3 ⬇️dose reduce to 40mg 🩻scans: PR lasts for one year 🫁single new pulm met 🧐What treatment option do you consider next after progression of pembro/axi and cabo? (@katy_beckermann)

0/16 #TumorBoardTuesday #RCC 👨🏻‍🏫Mini tweetorial 8👩🏻‍🏫 📌TKI monotherapy after prior IO 📍2L ✨Keynote-146: lenvatinib+pembro 55.8% ORR ✨CaboPoint: cabozantinib 31.7% ORR (prior IO/IO) & 25% (prior IO/TKI) 📍3L/4L ✨Tivo-3: prior IO/TKI fail, tivozanib had 24% ORR @ChungHanLee3 (@katy_beckermann)

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/06srQ9xkwE 🤔@brian_rini @katy_beckermann taught us treating refractory #RCC test your 🧠 with quick❓ 🧐What tx? 64yo 👴🏽 met RCC (🫁 & adrenal) asympt dz progress (liver) 18mos pembro/axit Wants aggressive tx (@katy_beckermann)

13/16 #TumorBoardTuesday Back to case🔎 64yo👨🏼‍🦳 met #RCC to 🫁 & adrenal 💊pembro/axitinib 📆18 mos PD to liver 🩻PR on cabo: single growing met 💊Cabo & SBRT 🙌🏽 SD for 6 mos 🩻scans: growth in liver & 🫁 🧐What tx do you consider next after progression of pembro/axi and cabo? (@katy_beckermann)

15a/16 #TumorBoardTuesday 🧑🏼‍🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (@katy_beckermann)

Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD (@urotoday)

Exciting developments in urothelial cancer treatment! Enfortumab vedotin, sacituzumab govitecan, and derazantinib are showing promise. Looking forward to EV and pembrolizumab results in first-line and MIBC. SG vs. chemo in platinum refractory disease is generating buzz.… https://t.co/XrJPm7T3jG (@nataliagandur)

My dads late stage melanoma shrank 30% in 6 months on Keytruda but unfortunately had done too much damage already to save his life. Early detection and treatment is the key (@Studio26151)

Pivotal ph2 study in @NatureMedicine showing that combining T-cell gene inflam signat and #TMB in NSCLC stratifies ORR to 1L Pembro plus either lenva/CTLA4/LAG3 combos. 50-60% ORR in “double-high” cohort. 👏@DrRoyHerbstYale @danieltanmd @EnriquetaFelip https://t.co/BaCSZtbaQ9 (@g_mountzios)

🗞️ Published in @TheLancetOncol and co-authored by VHIO’s @crisuarez08, results from the single-arm phase II KEYNOTE-B61 clinical trial support the use of pembrolizumab plus lenvatinib in patients with previously untreated advanced non-clear cell renal cell carcinoma. ➕… https://t.co/qUn891LZBA (@VHIO)

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/yU9CWV30fx (@OncLive)

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/RQML5zNQnC (@OncLive)

An ongoing phase II study led by @DrRoyHerbstYale shows combining pembrolizumab w/other treatments ⬇️ the size of target tumors, resulting in a ⬆️ response rate for patients w/advanced #NSCLC. #lcsm #KEYNOTE495 @SmilowCancer @YaleMed @YNHH @YaleThoracic https://t.co/8nzR0RsY2v (@YaleCancer)

The sustained OS benefit observed with pembrolizumab and lenvatinib in the CLEAR study solidifies the doublet’s use as a preferred option for the frontline treatment of patients with advanced RCC. @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/Jmjj0bMNuC (@OncLive)

⬆️ FAKi Boosts Anti-PD1 Immunotherapy in Pancreatic Cancer @DrArsenOsipov @danwpaterson @VerastemOncolog @PanCAN @lustgartenfdn @CpcrMsk @DanaFarber_Hale @jgong15 @CedarsSinai @ASCO #defactinib #pembrolizumab #CXCR4 #PDAC 🔻 https://t.co/OQHKJByl0J (@CrozrX)

Guess who stopped by? @ChungHanLee3, of @MSKCancerCenter! Thanks for speaking with us about the final results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell RCC #kcsm @kidneycan (@OncLive)

We spoke with @ChungHanLee3 from @MSKCancerCenter on the use of lenvatinib and pembrolizumab in patients with RCC. #kicsm | @kidneycan (@CancerNetwrk)

⭐️Huge congrats to our friends & colleagues ⁦@jeanyvesblay⁩ ⁦⁦@drcmassard⁩ from France for publishing this study 👉🏼Pembrolizumab in patients with rare & ultra-rare sarcomas (AcSé Pembrolizumab) ⁦@TheLancetOncol⁩ ⁦@OncoAlert⁩ https://t.co/FoSVuMFgKc (@VivekSubbiah)

#Hematology #Pembrolizumab in relapsed or refractory primary mediastinal large B-cell #lymphoma #PMBCL: final analysis of KEYNOTE-170 | ⁦@BloodJournal⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm https://t.co/u2dY4mXYfu (@DrRaulCordoba)

5/ 📊 After watching @DrMMurphy's video, what approach would you take to manage asymptomatic or symptomatic, grade 1 or 2 hypothyroidism in a woman w/ #endometrialcancer who is receiving pembrolizumab treatment❓ #ECBrief (@SoMeCME)

Of course, where ICPI and TKI durable responses lie on this axis is anyone’s guess…. I have my first patients about to hit FIVE years from completing their two years of Pembrolizumab for stage IV lung cancer… (@OncoloJo)

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free as adjuvant therapy in patients with resected melanoma, according to research led by @jasonlukemd. @OncLive https://t.co/gGyubaTBDO (@UPMCHillmanCC)

⭐️KEYNOTE-B61 single-arm, ph 2 trial of first-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma, 78 of 158 patients had a confirmed objective response (49%; 95% CI 41–57) @TheLancetOncol @OncoAlert @AlbigesL https://t.co/59ZG4tZHVI (@VivekSubbiah)

📢 eNewsletter Top 5 #lungcancer treatments from #ASCO23 1️⃣ ADAURA trial improved OS with adjuvant osimertinib. 2️⃣ Keynote 671 perioperative chemo w/ pembrolizumab. and 3 more @JackWestMD @cancergrace @cityofhope https://t.co/KGGx0d2AGv (@oncologytube)

After a great presentation at @ASCO #ASCO23, full paper just out @TheLancetOncol Keynote B61: 🚹Non-clear cell mRCC 💊Pembrolizumab+Lenvatinib 1st line 🎯ORR:49%, CR:6% @DrChoueiri @AlbigesL @ChungHanLee3 @OncoAlert @DrYukselUrun https://t.co/pHrrelHSLb (@yekeduz_emre)

13/15 #TumorBoardTuesday What about DatoDXd in localized TNBC? ✨TROPION-Breast03 Phase 3 Dato-DXd +/- durvalumab in pts with residual TNBC after neoadj Rx ➡️Control: capecitabine +/- pembrolizumab 🔮Looking forward to results comparing adj ADCs to SOC! 📚https://t.co/lmZxMfMj03 (@ArielleMedford)

8/15 #TumorBoardTuesday 📌What about adjuvant SG? Studies ongoing ✨ASCENT-05/OptimICE-RD (AFT-65) 📍randomized Phase 3 📍adj SG + pembro vs pembro +/- cape in pt with TNBC & residual dz after surgery✂️ cT1-T3 (any N) 🏁Primary endpoint IDFS 📚@stolaney1 https://t.co/3rJYiZke5I (@ArielleMedford)

Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23 full text: https://t.co/QioxQEiKho Thanks to all who change rareRCC pts Tx! (@AlbigesL)

.@DrRoyHerbstYale & colleagues share the interim results of an adaptive phase II #clinicaltrial of pembrolizumab-based combo therapy in #NSCLC, providing an individualized approach to treatment.#lcsm @SmilowCancer @YaleMed @NatureMedicine @OncoAlert @YNHH https://t.co/o80Sqc5T5d (@YaleCancer)

Recent advances in GU cancer: 1st line EV/pembro, ctDNA & SG in bladder ca. In RCC: 1st line triplet therapy, adjuvant IO and retreatment with immune therapy (CONTACT3/C313/564). Prostate ca: 1st line triplets (PEACE) and PARPi are covered @ChrisSweens1 https://t.co/mcbnz811ck (@tompowles1)

#Pembrolizumab plus #Chemotherapy in Advanced #EndometrialCancer 👉https://t.co/j9SQBGqkC6 @NEJM @Rne_md @CarryAghaj (@davidhenrymd)

This study not relevant anymore in second-line because shifting IO to first-line#first-line study efti+pembro coming to an end👊👊#chemo-free regimens welcome in HNSCC💥 (@WLybaert)

The combination of pembrolizumab + axitinib continued to improve OS, PFS, & ORR over sunitinib monotherapy in patients with treatment-naïve clear cell RCC. @brian_rini @VUMChealth #kcsm https://t.co/tKcszvDygl (@OncLive)

Great presentation by our colleague and friend @boutrosand on 2nd day of this Young @AIOMtweet 2023 on melanoma. 🔎 focus on: 1. mRNA vaccine + Pembro promising adjuvant therapy 2. IPI+NIVO 1st standard line even in BRAFm 3. Tebentafusp standard tp for uveal metastatic melanoma (@Lucarecco)

Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/4CP5RKH4Vq (@OncLive)

Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/2uj87xQ7pv (@OncLive)

According to the phase 1/2 EV-103 trial, enfortumab vedotin & pembro generated durable responses in locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. @shilpaonc @ClevelandClinic #ASCO23 #blcsm #oncology https://t.co/n4P8EHsvZV (@OncLive)